Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (780)	2/20/2000 3:56:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 1494

John, I've been long NTII for a couple of years now and attended the last two annual stockholders meetings. With a weighted average purchase price around $1, I've had my eye on $10/share as a milestone event. However, we are fast approaching that mark in an impressively progressive manner, and not in a single big spike on a news release. I would be interested to hear your view on how high the stock price might go by the end of the year if we stay on track with the company's goals of a big pharma partnership for the Phase III diabetic neuropathy trial and good results in the AIDS-related dementia & neuropathy trial. Here's a link to a ranked listing of all biotechs with a market cap above $100 million. Message 12894739 NTII's market cap is currently $64.8 million. On a comparative value basis, where do you think NTII's market cap should be after meeting this year's milestones? Marc